Symbol="ELOX"
AssetType="Common Stock"
Name="Eloxx Pharmaceuticals Inc"
Description="Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on developing ribonucleic acid modulator drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Waltham, Massachusetts."
CIK="1035354"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="TRADE & SERVICES"
Industry="SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH"
Address="950 WINTER STREET, WALTHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="14687900"
EBITDA="-28878000"
PERatio="None"
PEGRatio="None"
BookValue="-7.52"
DividendPerShare="0"
DividendYield="0"
EPS="-14.24"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.712"
ReturnOnEquityTTM="-6.15"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-14.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="55"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="6.31"
EVToRevenue="-"
EVToEBITDA="0.141"
Beta="2.678"
num_52WeekHigh="19.2"
num_52WeekLow="1.696"
num_50DayMovingAverage="6.02"
num_200DayMovingAverage="4.993"
SharesOutstanding="2166400"
DividendDate="2017-12-20"
ExDividendDate="None"
symbol="ELOX"
open="6.50"
high="6.96"
low="6.49"
price="6.78"
volume="58325.00"
latest_trading_day="2023-08-04"
previous_close="6.50"
change="0.28"
change_percent="4.3077%"
aroon_positive_momentum_days="97"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="97"
Volume_recent_avg="881891"
Change_recent_avg="0.08"
Delta_recent_avg="0.94"
Variance_recent_avg="0.47"
Change_ratio_recent_avg="0.25"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="97"
Aroon_momentum_negative="3"
image_negative_thumbnail_id_1="115"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0061.jpeg"
image_negative_thumbnail_id_2="164"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0012.jpeg"
image_neutral_thumbnail_id_1="526"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0073.jpeg"
image_neutral_thumbnail_id_2="432"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="1015"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0177.jpeg"
image_positive_thumbnail_id_2="599"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0109.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
